639 related articles for article (PubMed ID: 33870886)
21. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).
Román GC; Gracia F; Torres A; Palacios A; Gracia K; Harris D
Front Immunol; 2021; 12():653786. PubMed ID: 33981305
[TBL] [Abstract][Full Text] [Related]
22. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
Chagla Z
Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835
[TBL] [Abstract][Full Text] [Related]
23. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.
Aldali J; Meo SA; Al-Khlaiwi T
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109
[TBL] [Abstract][Full Text] [Related]
24. Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.
Tobaiqy M; MacLure K; Elkout H; Stewart D
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835256
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 booster vaccine willingness.
Sønderskov KM; Vistisen HT; Dinesen PT; Østergaard SD
Dan Med J; 2021 Dec; 69(1):. PubMed ID: 34913428
[TBL] [Abstract][Full Text] [Related]
26. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?
Cross S; Rho Y; Reddy H; Pepperrell T; Rodgers F; Osborne R; Eni-Olotu A; Banerjee R; Wimmer S; Keestra S
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34937701
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 vaccine willingness amongst patients with mental illness compared with the general population.
Jefsen OH; Kølbæk P; Gil Y; Speed M; Dinesen PT; Sønderskov KM; Østergaard SD
Acta Neuropsychiatr; 2021 Oct; 33(5):273-276. PubMed ID: 33998428
[TBL] [Abstract][Full Text] [Related]
28. Adverse events following administration of COVID-19 vaccines in Saudi Arabia.
Alqahtani S; Jokhdar H; Al-Tawfiq JA; Al-Otaibi S; Assiri A; Almudarra S; Alabdulkareem K; Haji A
Sci Rep; 2022 Nov; 12(1):19551. PubMed ID: 36379996
[TBL] [Abstract][Full Text] [Related]
29. [Temporary suspension of AstraZeneca's vaccine; a reconstruction].
Maas DPMSM; Kramers C; Smit HJCA; Middeldorp S; Helsloot I
Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914428
[TBL] [Abstract][Full Text] [Related]
30. Reporting of AstraZeneca studies may have caused vaccine reservations.
Bignardi G
BMJ; 2021 Apr; 373():n937. PubMed ID: 33846122
[No Abstract] [Full Text] [Related]
31. Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy.
Darweesh O; Khatab N; Kheder R; Mohammed T; Faraj T; Ali S; Ameen M; Kamal-Aldin A; Alswes M; Al-Jomah N
PLoS One; 2022; 17(11):e0274526. PubMed ID: 36399454
[TBL] [Abstract][Full Text] [Related]
32. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine.
Awada B; Abdullah L; Kurban M; Abbas O
J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985
[No Abstract] [Full Text] [Related]
33. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.
Barnabas RV; Wald A
Ann Intern Med; 2021 Apr; 174(4):552-553. PubMed ID: 33395339
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population.
Edwards B; Biddle N; Gray M; Sollis K
PLoS One; 2021; 16(3):e0248892. PubMed ID: 33760836
[TBL] [Abstract][Full Text] [Related]
35. Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign.
Vallée A; Chan-Hew-Wai A; Bonan B; Lesprit P; Parquin F; Catherinot É; Choucair J; Billard D; Amiel-Taieb C; Camps È; Cerf C; Zucman D; Fourn E
Public Health; 2021 Jul; 196():135-137. PubMed ID: 34198072
[TBL] [Abstract][Full Text] [Related]
36. Ischemic stroke after AstraZeneca (Covid-19) vaccination.
Alammar MA
Saudi Med J; 2021 Oct; 42(10):1136-1139. PubMed ID: 34611009
[TBL] [Abstract][Full Text] [Related]
37. Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen.
Soltani Hekmat A; Javanmardi K
Biomed Res Int; 2021; 2021():7702863. PubMed ID: 34734086
[TBL] [Abstract][Full Text] [Related]
38. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
[No Abstract] [Full Text] [Related]
39. Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia.
AlRuthia Y; Al-Salloum HF; Almohammed OA; Alqahtani AS; Al-Abdulkarim HA; Alsofayan YM; Almudarra SS; AlQahtani SH; Almutlaq A; Alabdulkareem K; Balkhi B; Almutairi HT; Alanazi AS; Asiri YA
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214781
[TBL] [Abstract][Full Text] [Related]
40. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients.
Sellaturay P; Gurugama P; Harper V; Dymond T; Ewan P; Nasser S
Clin Exp Allergy; 2022 Jan; 52(1):12-17. PubMed ID: 34822190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
